| Similar Articles |
|---|
 |
The Motley Fool
March 30, 2006
Stephen D. Simpson |
Arrow International's Dead Release Results at this medical device manufacturer look better than they really are. Investors, take note.   |
The Motley Fool
January 6, 2006
Stephen D. Simpson |
Off Course at Arrow International It's going to take time for the medical device company to add capacity; will customers still be waiting on the other side? Investors, take note. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
A Bard's Tale The advanced medical technology company's stock already reflects new products' potential. Still, life in the med-tech sector could get more interesting in the coming quarters. Investors, take note. |
The Motley Fool
October 6, 2006
Matthew Crews |
Arrow International Keeps on Target Investors, with Arrow's fourth quarter and fiscal 2006 earnings in the bag, now is a good time for a checkup. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry. |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
FoxHollow-ed Out Worries about guidance may be giving investors a second crack at this med-tech stock. |
The Motley Fool
February 5, 2007
Ryan Fuhrmann |
Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note. |
The Motley Fool
March 28, 2006
Rich Smith |
Foolish Forecast: Arrow Nocks The medical products maker is having a tough time of things, margins-wise. Investors, do better days lie ahead? |
The Motley Fool
July 13, 2005
Stephen D. Simpson |
Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history. |
The Motley Fool
April 9, 2010
Brian Orelli |
Is Boston Scientific Turning It Around? Selling off a pair of units could help. |
The Motley Fool
August 4, 2006
Stephen D. Simpson |
SilverHawk Flying Just Fine, Thanks With med-tech company FoxHollow Technologies, there is growth and risk in equal measure. Investors, take note. |
The Motley Fool
October 19, 2005
Stephen D. Simpson |
Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea. |
The Motley Fool
April 21, 2006
Stephen D. Simpson |
Bard Rolls On Nothing flashy here, but at the right price, this would be an interesting med-tech play. Investors, take note. |
The Motley Fool
September 2, 2005
Stephen D. Simpson |
Can Arrow International Straighten Up? Can the medical products maker overcome capacity constraints and get the top line flying again? Investors, take note. |
The Motley Fool
January 11, 2008
Brian Orelli |
Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008. |
The Motley Fool
January 26, 2007
Matthew Crews |
Bard's Costly Quarter? The medical device company suffered from multiple one-time charges. Investors who've seen the cup as half full have fared much better here than with many other med-tech companies. |
The Motley Fool
July 26, 2006
Stephen D. Simpson |
Aspect Gives Investors Nightmares The med tech company continues to grow, but high volatility is likely to follow. |
The Motley Fool
July 27, 2005
Stephen D. Simpson |
Back Pain for Shorts? Kyphon continues to defy its skeptics. A developer of minimally invasive technology for the spine, the company saw revenue in the second quarter grow 48% as the U.S. business grew about 41% and overseas sales climbed 99%. Investors, take note. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
Cytyc Still Stands On Its Own Despite apparent doubts about some mergers, the med-tech company is still growing strongly. Investors, take note. |
The Motley Fool
May 9, 2005
Stephen D. Simpson |
Integra LifeSciences Strikes a Nerve The med-tech company's missed quarter coupled with some slightly disappointing guidance caused investors to lose a bit of faith, sending the shares down more than 15% at one point. |
The Motley Fool
November 13, 2006
Anders Bylund |
Foolish Forecast: Tyco Still Ticking The diversified manufacturing and service company is set to report fourth-quarter and full-year earnings. Investors, here is a primer on the company and its current outlook. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Kensey Nash: Now the Comeback Kid? Strong results from a new device might be reason for optimism. Investors should still keep an eye on the valuations here and err on the side of cheapness. |
